Single Cell Gene Expression Analysis for Tumor Heterogeneity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing gene expression in single cells are limited in their ability to accurately identify and characterize different cell populations within heterogeneous tumor samples, particularly in cancers where mixed populations of cells with varying signaling pathways contribute to treatment resistance and relapse.
Innovation Solution
The method involves randomly partitioning individual cells from a tumor into discrete locations, performing transcriptome analysis on a plurality of genes, and using clustering analysis to identify distinct cell populations, allowing for the identification of different cell types and therapeutic targets within a heterogeneous tumor sample.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If global gene expression analysis is performed on bulk tumor samples, then overall gene expression patterns can be identified, but the ability to detect and characterize specific cell populations within heterogeneous tumors is limited
Solution Approach 1:
The patent applies segmentation by dividing bulk tumor samples into individual single cells through microfluidic devices that physically separate and isolate individual cells. This allows transcriptome analysis to be performed on each cell individually, enabling precise identification of specific cell populations (such as cancer stem cells versus differentiated cells) that would be masked in bulk analysis. The segmentation process uses microfluidic channels and barriers to distribute single cells across multiple locations for parallel processing.
Solution Approach 2:
The patent transitions from bulk tissue analysis to single-cell resolution, adding a dimensional level of detail that reveals cellular heterogeneity. By moving from the macro level (bulk tumor) to the micro level (individual cells), the system enables detection of rare cell types and subtle expression patterns that are lost in averaged bulk measurements.
2Measurement precision
If transcriptome analysis is performed on all genes in single cells, then comprehensive cell population identification is achieved, but analysis time and computational resources increase significantly
Solution Approach 1:
The patent implements partial action by selecting and analyzing only a subset of genes (e.g., 50-200 genes) rather than performing complete whole-transcriptome sequencing on all genes. This targeted approach focuses on genes most informative for distinguishing cell populations, such as stem cell markers versus differentiation markers. The partial action principle reduces computational burden and analysis time while maintaining sufficient accuracy for cell type identification and characterization.
Solution Approach 2:
The patent applies preliminary action by pre-selecting and pre-processing genes for analysis before performing single-cell transcriptome sequencing. Reference datasets and gene selection criteria are established in advance based on known cellular markers and pathways. This preliminary preparation enables more efficient analysis by focusing computational resources on the most relevant genes rather than processing the entire genome for each cell.
3Reliability
If conventional bulk RNA sequencing is used, then overall gene expression can be measured, but treatment resistance mechanisms in specific cell subpopulations remain undetected
Solution Approach 1:
The patent segments bulk tumor samples into individual single cells to detect treatment resistance mechanisms at the cellular level. By isolating and analyzing individual cells, the system can identify which specific cell subpopulations (e.g., cancer stem cells versus differentiated cells) express resistance genes and pathways. This segmentation enables detection of heterogeneity in treatment responses that is completely masked in bulk analysis.
Solution Approach 2:
The patent applies local quality by examining gene expression patterns at the individual cell level rather than averaging across the entire tumor. This allows identification of locally distinct cell populations with different resistance profiles, enabling prediction of which specific cell subpopulations will respond to or resist treatment. The local quality approach reveals spatial and functional heterogeneity that is lost in bulk measurements.
Data Source
Figure 1A1
Figure 1A2
Figure 1A3
AI summary
Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.